Advil PM and Sitagliptin Phosphate

• Generic Name: diphenhydramine / ibuprofen
• Dosage Forms: tablet, coated
• Other Brand Names: Advil PM, Advil PM Liqui-Gels, Ibuprofen PM, Motrin PM

Diphenhydramine is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose. Antihistamines can cause drowsiness, which can aid in the treatment of occasional sleep problems (insomnia).

Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID). Ibuprofen works by reducing hormones that cause inflammation and pain in the body.

Advil PM is a combination medicine used to treat occasional insomnia associated with minor aches and pains.

Advil PM is not for use in treating sleeplessness without pain, or sleep problems that occur often.

Advil PM may also be used for purposes not listed in this medication guide.

• Generic Name: sitagliptin
• Dosage Forms: n.a.
• Other Brand Names: Januvia

Used as monotherapy as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Used in combination with immediate- or extended-release metformin given separately or as a fixed combination (Janumet or Janumet XR, respectively) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

Used in fixed combination with ertugliflozin (Steglujan) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both drugs is appropriate.

Used in combination with other oral antidiabetic agents (e.g., metformin, a sulfonylurea, a thiazolidinedione [peroxisome proliferator-activated receptor-γ agonist]) or insulin as an adjunct to diet and exercise in patients with type 2 diabetes mellitus who have not achieved adequate glycemic control with one or more oral antidiabetic agents and/or insulin.

American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) suggests a DPP-4 inhibitor as one of several alternatives for initial monotherapy in patients with metformin contraindications (e.g., renal disease, hepatic disease, GI intolerance, risk of lactic acidosis). DPP-4 inhibitors also recommended as part of combination therapy, particularly with both postprandial and fasting plasma glucose elevations.

Not indicated for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis; insulin is required in these conditions.